Transplant immunology最新文献_第2页

Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-30 DOI: 10.1016/j.trim.2025.102181

Mariano Berro MD PhD , Silvina Odstrcil MD , Milagros Frassa MD , Maria M. Rivas MD , Jose I Trucco , Ines Paganini MD , Gustavo D. Kusminsky MD , Daniel Couriel MD

{"title":"Impact of tacrolimus time in therapeutic range (TTR) on early post transplantation outcomes","authors":"Mariano Berro MD PhD , Silvina Odstrcil MD , Milagros Frassa MD , Maria M. Rivas MD , Jose I Trucco , Ines Paganini MD , Gustavo D. Kusminsky MD , Daniel Couriel MD","doi":"10.1016/j.trim.2025.102181","DOIUrl":"10.1016/j.trim.2025.102181","url":null,"abstract":"<div><div>Tacrolimus is a backbone for immunosuppression after allogeneic stem cell transplantation (AlloSCT). There is no sufficient kinetic data demonstrating the consistency of maintaining therapeutic levels. Herein, we measured the kinetic of therapeutic range (TTR) and its impact on outcomes of AlloSCT. Our local observational cohort included 186 adult AlloSCT performed at Hospital Austral between January 2012 and December 2019. An additional external cohort included 307 adult patients with AlloSCT from the University of Utah. We defined adequate TTR as >75 % of the measurements between 5.0 and 15.0 ng/mL during the first 30 days post-transplantation. In our local cohort, 55 % of patients had adequate TTR values. Primary graft failure was significantly lower in patients with adequate TTR (2 %, 95 % CI 0.5–7.7 % vs. 10 %, 95 % CI 5–18 %, <em>p</em> = 0.01). Non relapse mortality (NRM) was significantly lower with adequate TTR (17 %, 95 % CI 11–26 % vs. 33 %, 95 % CI 24–43 %; <em>p</em> < 0.01). Similarly, the external cohort had an NRM value significantly reduced in patients with adequate TTR values. In the pooled data analysis of local and external groups (<em>n</em> = 493), the TTR value below minimal range (≥25 % of measurements <5 ng/mL) was an independent risk factor for graft failure, as well as for NRM rate (44 %, 95 % CI 30–57 % vs. 18 %, 95 % CI 15–22 %) (<em>p</em> < 0.001) and lower OS at 3 years (47 %, 95 % CI 26–55 % vs. 56 %, 95 % CI 49–59 %, p < 0.001).</div><div>These findings showed the importance of adequate TTRs during the first month after AlloSCTs. Sub-therapeutic TTR values were associated with worse survival outcomes.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102181"},"PeriodicalIF":1.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel CD62L depleted donor lymphocyte infusion with T-cell receptor alpha-beta depleted haploidentical hematopoietic stem cell transplantation in children

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-30 DOI: 10.1016/j.trim.2025.102176

Daniel Ka Leung Cheuk , Pamela Pui Wah Lee , Wilson Yau Ki Chan , Godfrey Chi Fung Chan , Chi Chiu So , Wing Hang Leung

{"title":"Novel CD62L depleted donor lymphocyte infusion with T-cell receptor alpha-beta depleted haploidentical hematopoietic stem cell transplantation in children","authors":"Daniel Ka Leung Cheuk , Pamela Pui Wah Lee , Wilson Yau Ki Chan , Godfrey Chi Fung Chan , Chi Chiu So , Wing Hang Leung","doi":"10.1016/j.trim.2025.102176","DOIUrl":"10.1016/j.trim.2025.102176","url":null,"abstract":"<div><div>Ex-vivo depletion of donor CD45RA+ naïve T-cells can reduce graft-versus-host-disease (GVHD) in haploidentical hematopoietic stem cell transplantation (HSCT) while providing memory T-cells to reduce infections. CD62L is another marker of naïve T-cells. Depletion of CD62L+ cells may offer advantages of removing central memory T-cells which may also cause mild GVHD, and retain CD45RA+ effector memory T-cells (TEMRA). We aimed to evaluate the depletion efficiency, safety and immunoreconstitution after novel CD62L depleted donor lymphocyte infusion (DLI) with T-cell receptor (TCR)-αβ depleted haploidentical HSCT. Children with malignant or non-malignant diseases who underwent the first TCRαβ depleted haploidentical HSCT were recruited to receive CD62L depleted DLI on day 0 at a dose of 1 × 10<sup>6</sup>/kg or 5 × 10<sup>6</sup>/kg CD3+CD62L- cells using the CliniMACS device. Six children aged 0.3–15 years received 4.6-10 × 10<sup>6</sup>/kg CD34+ cells. CD62L depletion resulted in undetectable CD3+CD62L+ cells in 4 patients and 3.39–3.52 log reduction in 2 patients. Infusion was well-tolerated. All patients had neutrophil and platelet engrafted early (medians 10 and 9.5 days respectively) with 100 % donor chimerism. Only one patient had grade 1 acute GVHD. None had chronic GVHD. Post-transplant recovery of CD3+ cells reached a median of 117/uL at 1 month and as high as 352/uL at 3 months. TEMRA cells were present at 1 month (median 2 cells/uL) and increased 3 months post-transplant (median 21 cells/uL). In conclusion, CD62L depletion is highly efficient and appears safe and does not affect engraftment. It provides TEMRA and effector memory T-cells to protect the recipient against infections. Risk of GVHD is low.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102176"},"PeriodicalIF":1.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical application of biological agents in rheumatoid arthritis.

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-30 DOI: 10.1016/j.trim.2025.102187

Lianying Cheng, Xiaofeng Rong

{"title":"Clinical application of biological agents in rheumatoid arthritis.","authors":"Lianying Cheng, Xiaofeng Rong","doi":"10.1016/j.trim.2025.102187","DOIUrl":"https://doi.org/10.1016/j.trim.2025.102187","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder primarily distinguished by synovial inflammation, which, as the disease evolves, can lead to bone erosion and destruction. Consequently, the pivotal strategy in preventing joint damage and fostering functional recovery lies in the effective management of synovial inflammation. Disease-modifying antirheumatic drugs (DMARDs) and prednisone therapy remain the first-line treatments for RA. However, in instances of refractory RA, these medications may fall short in adequately controlling inflammation, and they are often accompanied by several adverse effects, including limited bioavailability, therapeutic resistance, and potentially toxic side effects. Given these challenges, the identification of targeted therapies to manage disease activity and diminish inflammation becomes imperative.Recently, biologic agents for the treatment of RA have garnered significant attention owing to their minimal side effect profile, reduced potential for drug dependence, and their precise therapeutic action directly on target cells. This review provides a comprehensive exploration of advancements in biologics that target and inhibit inflammatory cytokine receptors, specifically TNF-α, IL-6, and IL-1β, as well as B lymphocyte receptors, TLR4, nanodrugs, and Janus kinase (JAK) inhibitors in the context of RA. By providing innovative perspectives and strategies for the treatment of this condition, this review contributes to the ongoing efforts to refine and improve the therapeutic landscape for RA.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102187"},"PeriodicalIF":1.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterizing the urobiome and associated metabolic profiles during acute rejection in renal transplant patients: A pilot study 肾移植患者急性排斥反应期间尿组和相关代谢特征的表征：一项初步研究。

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-06 DOI: 10.1016/j.trim.2024.102170

David Harriman , Alex Ng , Monica Bronowski , Herman Kazakov , Christopher Nguan , Thien Dang , Karen Sherwood , Aaron Miller , Dirk Lange

{"title":"Characterizing the urobiome and associated metabolic profiles during acute rejection in renal transplant patients: A pilot study","authors":"David Harriman , Alex Ng , Monica Bronowski , Herman Kazakov , Christopher Nguan , Thien Dang , Karen Sherwood , Aaron Miller , Dirk Lange","doi":"10.1016/j.trim.2024.102170","DOIUrl":"10.1016/j.trim.2024.102170","url":null,"abstract":"<div><div>Characteristic alterations in the urinary microbiome, or urobiome, are associated with renal transplant pathology. To date, there has been no direct study of the urobiome during acute allograft rejection. The goal of this study was to determine if unique urobiome alterations are present during acute rejection in renal transplant recipients. We performed shotgun metagenomic sequencing of 32 mid-stream urine samples obtained from 15 transplant recipients pre-transplant, 1- and 3-months post-transplant, and at time of rejection discovered with for-cause biopsy. Within individuals, there was a 40–60 % difference in urobiome composition from pre-to-post-transplant in both rejectors and non-rejectors. The taxa Ureaplasma was enriched in rejectors compared to non-rejectors. However, a greater number of microbial genes were enriched in non-rejectors compared to rejectors, except for genes associated with tetracycline resistance, the lysophosphatidic acid synthesis pathway, and tryptophanyl-tRNA synthetase. Together, our findings suggest that the urobiome is significantly altered post-transplant with certain taxa and/or microbial genes potentially associated with acute allograft rejection/inflammation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102170"},"PeriodicalIF":1.6,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lower basophil count after anti-thymocyte globulin induction is associated with lower incidence of acute cellular rejection in heart transplant recipients 抗胸腺细胞球蛋白诱导后较低的嗜碱性粒细胞计数与心脏移植受者较低的急性细胞排斥发生率相关。

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-05 DOI: 10.1016/j.trim.2025.102173

Boško Skorić , Petra Mjehović , Mia Dubravčić Došen , Andrija Nekić , Dora Fabijanović , Nina Jakuš , Jure Samardžić , Ivo Planinc , Maja Čikeš , Hrvoje Gašparović , Davor Miličić

{"title":"Lower basophil count after anti-thymocyte globulin induction is associated with lower incidence of acute cellular rejection in heart transplant recipients","authors":"Boško Skorić , Petra Mjehović , Mia Dubravčić Došen , Andrija Nekić , Dora Fabijanović , Nina Jakuš , Jure Samardžić , Ivo Planinc , Maja Čikeš , Hrvoje Gašparović , Davor Miličić","doi":"10.1016/j.trim.2025.102173","DOIUrl":"10.1016/j.trim.2025.102173","url":null,"abstract":"<div><h3>Introduction</h3><div>While lymphodepletion is considered a therapeutic effect of rabbit anti-thymocyte globulin (rATG), a concomitant decrease in basophil count (BC) has unknown clinical effect.</div></div><div><h3>Objective</h3><div>To investigate the association between BC following rATG induction and acute cellular rejection (ACR) during the first post-HTx year.</div></div><div><h3>Methods</h3><div>Retrospective single-center study included 183 HTx recipients receiving rATG induction between 2010 and 2021 (mean age 52 ± 13 years, 23 % female). Absolute lymphocyte count (ALC), platelet (PLT) count and BC were assessed on days 0, 7, 14, and 21 following HTx. The primary outcome was the first ACR (grade ≥1B) within the first post-HTx year.</div></div><div><h3>Results</h3><div>Patients with ACR had significantly higher BC on day 14 (17/μL (IQR 9–43/μL) vs. 10/μL (IQR 4–19/μL), <em>p</em> = 0.050) and higher PLT on day 7 (143 × 10<sup>3</sup>/μL (IQR 103–168 × 10<sup>3</sup>/μL) vs. 105 × 10<sup>3</sup>/μL (IQR 68–141 × 10<sup>3</sup>/μL), <em>p</em> = 0.02), with higher ALC on day 14 (308/μL (IQR 171–530/μL) vs. 180/μL (IQR 93–317/μL), <em>p</em> = 0.016) and on day 21 (529/μL (IQR 240–610/μL) vs. 225/μL (IQR 121–328/μL), <em>p</em> < 0.001). In univariate analysis, ACR was associated with higher BC on day 14 (<em>p</em> = 0.004), higher PLT on day 7 (p = 0.02), higher ALC on days 14 (<em>p</em> = 0.04) and 21 (p < 0.001). Multivariable regression model showed the most significant association between higher BC on day 14 and ACR (<em>p</em> = 0.015).</div></div><div><h3>Conclusion</h3><div>Lower BC two weeks after rATG induction is associated with less ACR during the first post-HTx year.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102173"},"PeriodicalIF":1.6,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of complement inhibitors against refractory antibody-mediated rejection of lung transplantation: Two clinical cases 补体抑制剂对抗难治性抗体介导的肺移植排斥反应的有效性：两个临床病例。

IF 1.6 4区医学

Transplant immunology Pub Date : 2025-01-03 DOI: 10.1016/j.trim.2025.102174

Hadrien Mallet , Laurent Razat , Quentin Perrier , Amandine Briault , Christel Saint Raymond , Loic Falque , Lionel Rostaing , Bruno Degano , Pierrick Bedouch

{"title":"Effectiveness of complement inhibitors against refractory antibody-mediated rejection of lung transplantation: Two clinical cases","authors":"Hadrien Mallet , Laurent Razat , Quentin Perrier , Amandine Briault , Christel Saint Raymond , Loic Falque , Lionel Rostaing , Bruno Degano , Pierrick Bedouch","doi":"10.1016/j.trim.2025.102174","DOIUrl":"10.1016/j.trim.2025.102174","url":null,"abstract":"<div><div>Antibody-mediated rejection (AMR) has been recognized as a significant cause of acute and chronic lung allograft dysfunction after lung transplantation. Some treatments, eculizumab, an anti-complement (C)5 component monoclonal antibody (Mab), seem to have a promising effect in the management of some patients with AMR. We present two patients with acute AMR after lung transplantation who received the anti-C5 Mab therapy. In both cases, we identified the presence of C4d deposition in the peritubular capillaries on trans-alveolar biopsies, which suggested activation of complement in AMR. Prior to eculizumab therapy, both patients had also received immunoadsorption, courses of intravenous immunoglobulins (IVIG) and rituximab. For the first patient, we have shown that eculizumab can serve as an effective bridge to re-transplantation. For the second patient, we observed the absence of clinical and biological efficacy, and without a clear therapeutic efficacy the therapy with eculizumab had been discontinued after two months.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"89 ","pages":"Article 102174"},"PeriodicalIF":1.6,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoglobulin-like receptor genotype-associated protection from cytomegalovirus infection after liver transplantation. 免疫球蛋白样受体基因型对肝移植后巨细胞病毒感染的保护作用。

IF 1.6 4区医学

Transplant immunology Pub Date : 2024-12-27 DOI: 10.1016/j.trim.2024.102171

Shuxian Wang, Bo He, Huan Liu, Imran Muhammad, Jinzhen Cai, Feng Wang

{"title":"Immunoglobulin-like receptor genotype-associated protection from cytomegalovirus infection after liver transplantation.","authors":"Shuxian Wang, Bo He, Huan Liu, Imran Muhammad, Jinzhen Cai, Feng Wang","doi":"10.1016/j.trim.2024.102171","DOIUrl":"10.1016/j.trim.2024.102171","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) is a common clinical infection especially after organ transplantation and threaten the survival of recipients. Natural killer (NK) cells play an important role in the process of CMV infection. In this study, we want to explore that if the different of killer immunoglobulin-like receptors (KIRs) of NK cells could affect CMV infection.</p><p><strong>Methods: </strong>We study a cohort of 447 recipients after liver transplantation in our center. KIR-SSO Genotyping kit was used to detect the activated and inhibitory KIR genes. We determine the high-risk factors for CMV infection, and based on the KIR genotype, the recipients are divided into different groups, then the rate of CMV infection was analyzed.</p><p><strong>Results: </strong>CMV infection occurred in 32/447 (7.2 %) patients in the first year after the transplant surgery. We find that recipient age, Body Mass Index (BMI), Model for End-Stage Liver Disease (MELD) score, intubation time, and occurrence of Early Allograft Dysfunction (EAD) are high-risk factors for CMV infection. Comparing with the CMV-DNA turned negative, the percentage of lymphocyte, as well as the number of lymphocytes and CD4<sup>+</sup> lymphocytes decreased when the period of receipts' CMV-DNA tested positive. The rate of CMV infection in Tel-B/X genotype group is significantly lower than A/A genotype group.</p><p><strong>Conclusions: </strong>Our data indicates that KIR genes can affect CMV infection and provide potential clinical value following liver transplantation.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102171"},"PeriodicalIF":1.6,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tacrolimus-induced thrombotic microangiopathy (TMA) after heart and lung transplantation successfully treated with eculizumab. 他克莫司诱发的血栓性微血管病（TMA）在心肺移植后用eculizumab成功治疗。

IF 1.6 4区医学

Transplant immunology Pub Date : 2024-12-26 DOI: 10.1016/j.trim.2024.102169

Zein Kattih, Aldo Iacono, Christina Saikus, Michael Esposito, Zachary Kon, Maksim Korotun

引用次数: 0

Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. 小剂量emapalumab联合化疗治疗eb病毒相关噬血细胞淋巴组织细胞增多症的成人患者

IF 1.6 4区医学

Transplant immunology Pub Date : 2024-12-22 DOI: 10.1016/j.trim.2024.102162

Wenjuan Zhu, Fei Zhou, Yue Song, Shiyuan Zhou, Feng Du, Qian Zhu, Ziyi Wang, Liyun Bai, Jianhong Fu, Xiao Ma, Xiaojin Wu, Xuefeng He

引用次数: 0

High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection. 阿尔及利亚血液透析患者和一般人群中巨细胞病毒的高血清阳性率：移植后巨细胞病毒感染的中等风险患者

IF 1.6 4区医学

Transplant immunology Pub Date : 2024-12-22 DOI: 10.1016/j.trim.2024.102168

Lydia Lamara Mahammed, Zineb Omrani, Nourhene Bellachia, Lilya Meriem Berkani, Messaoud Saidani, Reda Djidjik

{"title":"High seroprevalence of CMV among Algerian hemodialysis patients and the general population: Intermediate-risk patients for post-transplant CMV infection.","authors":"Lydia Lamara Mahammed, Zineb Omrani, Nourhene Bellachia, Lilya Meriem Berkani, Messaoud Saidani, Reda Djidjik","doi":"10.1016/j.trim.2024.102168","DOIUrl":"10.1016/j.trim.2024.102168","url":null,"abstract":"<p><strong>Introduction: </strong>Cytomegalovirus (CMV) is a virus of the herpesviridae family. CMV infection is associated with increased morbidity and mortality in immunocompromised subjects such as hemodialysis patients and transplant recipients. The aim of our study was to determine the serological status of potential kidney recipients and donors in order to assess the risk of post-transplant CMV infection and disease.</p><p><strong>Patients and methods: </strong>We included 135 and 200 potential kidney transplant donors and recipients, respectively, who were tested for anti-CMV IgM and IgG by chemiluminescence on IMMULITE 2000 XPI®.</p><p><strong>Results: </strong>The prevalence of anti-CMV IgG was 95.50 % (95 % CI [92.63 %-98.37 %]) in hemodialysis patients and 96.30 % (95 % CI [93.12 %-99.48 %]) in potential kidney donors. The difference between the two groups was not significant (p = 0.721). Anti-CMV IgM were only detected in the sera of 13 hemodialysis patients and 3 healthy subjects. In both groups, the highest rate of anti-CMV IgG positivity was observed in subjects aged over 50 years (100 %), followed by those aged between 18 and 30 years old, with a slightly higher seroprevalence in men than in women.</p><p><strong>Conclusion: </strong>Our results suggest a high prevalence of anti-CMV IgG in potential kidney donors and recipients (D+/R+), who could be classified as an intermediate risk group for post-transplant CMV infection and/or disease.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102168"},"PeriodicalIF":1.6,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0